DB2313
Based on 7 publication(s) in Google Scholar
DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.48%
- CAS No.: 2170606-74-1
- Formule: C42H41FN8O2
- Masse moléculaire:708.83
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) DB2313
More- Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
- Nat Commun. 2026 Feb 24;17(1):3123. [Abstract]
- Nat Commun. 2025 Aug 4;16(1):7134. [Abstract]
- Adv Sci (Weinh). 2025 Jun;12(21):e2415205. [Abstract]
- Chem Biol Interact. 2024 Dec 1:404:111262. [Abstract]
- J Craniofac Surg. 2026 Mar 2. [Abstract]
- McGill University. 2026.
Customer Validation & Images
-
RT-PCR
-
ELISA
-
Flow Cytometry
-
Flow Cytometry
-
Histological Imaging/Staining
Activité biologique
IC50: 14 nM (PU.1)[1]
DB2313 treatment leads to a profound decrease in the growth of PU.1 URE–/– acute myeloid leukemia (AML) cells (IC50 of 7.1 μM), while showing little effect on normal hematopoietic cells at similar concentrations. DB2313 treatment leads to a 3.5-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells. DB2313 also leads to a significant decrease in clonogenicity in the second and third rounds of plating and a complete disruption of clonogenic capacity in the fourth and higher rounds of plating[1].
In AML cells, DB2313 decreases PU.1 occupancy on E2f1, Junb, and Csf1r promoters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells[1]
-
Dosage:17 mg/kg
-
Administration:Intraperitoneal injection; three times per week; for 3 weeks
-
Result:Decreased tumor burden and resulted in increased survival.
Chemical Information
-
CAS No. 2170606-74-1
-
Appearance Solid
-
Masse moléculaire 708.83
-
Formule C42H41FN8O2
-
Color Off-white to gray
-
SMILES
FC1=C(COC2=CC=C(C3=NC4=CC=C(C(NC(C)C)=N)C=C4N3)C=C2)C=CC=C1COC5=CC=C(C6=NC7=CC=C(C(NC(C)C)=N)C=C7N6)C=C5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Ann Rheum Dis
2024 Aug 20:ard-2024-226067. PMID: 39164066
DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
DB2313 (0.3 mg; i.p.; once every 3 d) downregulated IL-9 expression and the proportions of Th9 cells in the spleen and PBMCs of collagen-induced arthritis (CIA) mice.
DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
PU.1 inhibitor DB2313 (0.3 mg; i.p.; once every 3 d) suppressed IL-9 release from Th9 cells of collagen-induced arthritis (CIA) mice.
DB2313 purchased from MedChemExpress. Usage Cited in: Ann Rheum Dis. 2024 Aug 20:ard-2024-226067. [Abstract]
Effect of PU.1 inhibitor DB2313 (0.3 mg; i.p.; once every 3 d) on joint neovascularization in collagen-induced arthritis (CIA) mice.
-
Nat Commun
DNA-PK-mediated phosphorylation of STAT6 establishes a non-canonical type 2 immunity axis to prevent macrophage senescence. [Abstract]2026 Feb 24;17(1):3123. PMID: 41735318 -
Nat Commun
Unveiling genetic signatures of immune response in immune-related diseases through single-cell eQTL analysis across diverse conditions. [Abstract]2025 Aug 4;16(1):7134. PMID: 40759647
DB2313 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 4;16(1):7134. [Abstract]
DB2313 (660 nM) inhibited the transcription of CSF1R, CALM1, and SLC2A3 while promoting E2F in neutrophils.
DB2313 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 4;16(1):7134. [Abstract]
DB2313 (17 mg/kg; i.p.) decreased serum levels of MMP9 and MPO/DNA‐NETs in the murine MI/RI model.
-
Adv Sci (Weinh)
MMP9High Neutrophils are Critical Mediators of Neutrophil Extracellular Traps Formation and Myocardial Ischemia/Reperfusion Injury. [Abstract]2025 Jun;12(21):e2415205. PMID: 40151877 -
Chem Biol Interact
4-Hydroxybenzoic acid restrains Nlrp3 inflammasome priming and activation via disrupting PU.1 DNA binding activity and direct antioxidation. [Abstract]2024 Dec 1:404:111262. PMID: 39389441 -
J Craniofac Surg
PU.1 Inhibition Attenuates Neuroinflammation and Pyroptosis After Traumatic Brain Injury by Modulating Microglial Polarization. [Abstract]2026 Mar 2. PMID: 41769894 -
Solvant et solubilité
DMSO : 100 mg/mL (141.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.33 mg/mL (4.70 mM); Clear solution
This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 3.33 mg/mL (4.70 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3.33 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 5 mg/mL (7.05 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Iléana Antony-Debré, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017 Dec 1;127(12):4297-4313. [Content Brief]
[2]. Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4108 mL | 7.0539 mL | 14.1078 mL | 35.2694 mL |
| 5 mM | 0.2822 mL | 1.4108 mL | 2.8216 mL | 7.0539 mL | |
| 10 mM | 0.1411 mL | 0.7054 mL | 1.4108 mL | 3.5269 mL | |
| 15 mM | 0.0941 mL | 0.4703 mL | 0.9405 mL | 2.3513 mL | |
| 20 mM | 0.0705 mL | 0.3527 mL | 0.7054 mL | 1.7635 mL | |
| 25 mM | 0.0564 mL | 0.2822 mL | 0.5643 mL | 1.4108 mL | |
| 30 mM | 0.0470 mL | 0.2351 mL | 0.4703 mL | 1.1756 mL | |
| 40 mM | 0.0353 mL | 0.1763 mL | 0.3527 mL | 0.8817 mL | |
| 50 mM | 0.0282 mL | 0.1411 mL | 0.2822 mL | 0.7054 mL | |
| 60 mM | 0.0235 mL | 0.1176 mL | 0.2351 mL | 0.5878 mL | |
| 80 mM | 0.0176 mL | 0.0882 mL | 0.1763 mL | 0.4409 mL | |
| 100 mM | 0.0141 mL | 0.0705 mL | 0.1411 mL | 0.3527 mL |
DB2313 Related Classifications
HY-124629 Related Classifications
Powered by Bioz